Cargando…

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

BACKGROUND: Aromatase inhibitors (AI) reduce recurrence and death in patients with early-stage hormone receptor-positive (HR +) breast cancer. Treatment-related toxicities, including AI-induced musculoskeletal symptoms (AIMSS), are common and may lead to early AI discontinuation. The objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hertz, Daniel L., Smith, Karen Lisa, Zong, Yuhua, Gersch, Christina L., Pesch, Andrea M., Lehman, Jennifer, Blackford, Amanda L., Henry, N. Lynn, Kidwell, Kelley M., Rae, James M., Stearns, Vered
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239354/ https://www.ncbi.nlm.nih.gov/pubmed/34211496 http://dx.doi.org/10.3389/fgene.2021.662734

Ejemplares similares

Polymorphism rs2073618 of the TNFRSF11B (OPG) Gene and Bone Mineral Density in Mexican Women with Rheumatoid Arthritis
por: Nava-Valdivia, C. A., et al.
Publicado: (2017)

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
por: Dempsey, Jacqueline M., et al.
Publicado: (2018)

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
por: Gaillard, Stéphanie, et al.
Publicado: (2011)

Association between Osteoprotegerin rs2073618 polymorphism and peri-implantitis susceptibility: a meta-analysis
por: Xu, Min, et al.
Publicado: (2022)

SNP rs2073618 of the Osteoprotegerin Gene Is Associated with Diabetic Retinopathy in Slovenian Patients with Type 2 Diabetes
por: Mankoč Ramuš, Sara, et al.
Publicado: (2013)

Association of rs2073618 polymorphism and osteoprotegerin levels with hypertension and cardiovascular risks in patients with type 2 diabetes mellitus
por: Sailaja, A. Naga, et al.
Publicado: (2023)

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
por: Hertz, Daniel L., et al.
Publicado: (2016)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients
por: Wang, Jingxuan, et al.
Publicado: (2015)

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
por: Henry, N L, et al.
Publicado: (2010)

327 Nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer patients over age 65
por: Joyce, Elizabeth, et al.
Publicado: (2022)

Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients
por: Bell, Sarah G., et al.
Publicado: (2020)

OPG rs2073617 polymorphism is associated with upregulated OPG protein expression and an increased risk of intervertebral disc degeneration
por: Xue, Jing-Bo, et al.
Publicado: (2016)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021)

Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms
por: Henry, N Lynn, et al.
Publicado: (2021)

Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010)

Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)

Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture
por: Wu, Ying, et al.
Publicado: (2013)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013)

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy
por: Hertz, Daniel L., et al.
Publicado: (2018)

Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities
por: Grigorian, Nelly, et al.
Publicado: (2022)

Further thoughts on RS and composites
por: Quiros Carcelen, Mariano
Publicado: (2017)

Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015)

Vitamin D in the Prevention of Aromatase Inhibitor–Induced Musculoskeletal Symptoms: Is It Ready for Practice?
por: Brant, Jeannine
Publicado: (2012)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
por: Marcath, Lauren A., et al.
Publicado: (2018)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
por: Hack, C.C., et al.
Publicado: (2020)

Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
por: Young, Nicholas A., et al.
Publicado: (2022)

Analysis of the rs10046 Polymorphism of Aromatase (CYP19) in Premenopausal Onset of Human Breast Cancer
por: Zins, Karin, et al.
Publicado: (2014)

SPG/DPG/ÖPG Frühjahrstagung : Teilchenphysik
por: Collective
Publicado: (1987)

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
por: Ming, Jie, et al.
Publicado: (2020)

The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Effectiveness of intervention for aromatase inhibitor-associated musculoskeletal symptoms: A protocol for systematic review and meta-analysis
por: Meng, Hui, et al.
Publicado: (2022)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Increased serum OPG in atrophic nonunion shaft fractures
por: Marchelli, Daniele, et al.
Publicado: (2009)

Aromatase in the Human Brain
por: Azcoitia, Iñigo, et al.
Publicado: (2021)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
por: Eid, Riham, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aqt34o190tufj52v680na5djv2